# Pat Cotroneo

> Pat Cotroneo is a seasoned life sciences financial executive who spent over two decades at FibroGen, Inc. (now Kyntra Bio), serving as Chief Financial Officer from 2008 to 2021. During his tenure, he guided FibroGen through two defining transformations: its landmark 2014 IPO - the largest biotech public offering in 12 years - and its evolution into a commercial-stage company with the launch of roxadustat in China in 2019. With 25+ years of senior financial leadership in life sciences, Cotroneo built his career at Deloitte & Touche, SyStemix (a Novartis subsidiary), and ultimately FibroGen, where he oversaw finance, accounting, human resources, and information technology before transitioning to Executive Advisor to the CEO.

- **Role:** Executive Advisor to Chief Executive Officer at Kyntra Bio (formerly FibroGen)
- **Organizations:** FibroGen, Inc., Kyntra Bio, SyStemix, Inc., Genetic Therapy, Inc., Deloitte & Touche
- **Nationality:** American
- **Education:** Bachelor of Science (with honors), Louise M. Davies Scholar, University of San Francisco
- **Known for:** Guided FibroGen through its $167.7 million IPO in 2014, the largest biotech IPO in 12 years at $1.04 billion valuation, Led financial operations during FibroGen's transition from development-stage to commercial-stage company, Oversaw the commercial launch of roxadustat in China in 2019

## Career timeline

- **1987-1993** — Worked at Deloitte & Touche in various financial positions
- **1993-2000** — Controller at SyStemix, Inc. and Genetic Therapy, Inc. (both Novartis subsidiaries)
- **2000** — Joined FibroGen, Inc. as VP Finance & Controller
- **2008** — Appointed Chief Financial Officer of FibroGen, Inc.
- **2014** — Led FibroGen's IPO - $167.7M raise, largest biotech IPO in 12 years, $1.04B valuation
- **2019** — Oversaw financial operations for roxadustat's commercial launch in China
- **2021-09-06** — Retired as CFO of FibroGen; succeeded by Juan Graham
- **2021-09-07 to 2022-03-31** — Continued as Executive Advisor to the CEO to ensure smooth leadership transition

## Achievements

- Guided FibroGen through its $167.7 million IPO in 2014, the largest biotech IPO in 12 years at $1.04 billion valuation
- Led financial operations during FibroGen's transition from development-stage to commercial-stage company
- Oversaw the commercial launch of roxadustat in China in 2019
- Managed finance, accounting, human resources, and information technology at FibroGen
- 25+ years of senior financial leadership in the life sciences sector
- Recipient of the Louise M. Davies Scholar award at the University of San Francisco
- Graduated with honors from the University of San Francisco

## Latest updates

- **2021-08** — Announced retirement as CFO of FibroGen, Inc. after 21 years with the company
- **2021-09** — Succeeded as CFO by Juan Graham, a J&J veteran; transitioned to Executive Advisor to CEO role
- **2022-03** — Concluded service as Executive Advisor to the CEO of FibroGen (now Kyntra Bio)

## Links

- LinkedIn: http://www.linkedin.com/in/pat-cotroneo-8482734

---

Profile page: https://yespress.io/pat-cotroneo
Published by YesPress — https://yespress.io
Last updated: 2026-05-15